Medical Indications and Expected Benefits
GlutaOne 1200mg is an injectable glutathione formulation commonly prescribed for conditions associated with oxidative stress, such as chronic liver disease, neurodegenerative disorders, and certain dermatologic conditions. The primary factor before initiating therapy is confirming that the patient’s diagnosis aligns with evidence‑based indications and that the expected benefit outweighs potential risks.
Patient Eligibility Criteria
Assessing eligibility involves a multi‑step review:
- Diagnostic Confirmation
- Laboratory evidence of hepatic dysfunction (ALT/AST >2× ULN) or documented neurodegenerative pathology.
- Exclusion of acute infections or inflammatory flares that may mimic the target condition.
- Age and Comorbidity
- Adult patients (≥18 years) with stable comorbidities such as diabetes, hypertension, or mild renal impairment (eGFR ≥ 30 mL/min/1.73 m²) are generally suitable.
- Patients with decompensated cirrhosis (Child‑Pugh class C) or severe renal failure (eGFR < 30 mL/min) require dose adjustment or alternative therapy.
- Pregnancy and Lactation
- Glutathione is classified as Category B in pregnancy; however, injection safety data are limited. Breastfeeding mothers should be counseled on minimal systemic exposure.
Pre‑treatment Laboratory Assessments
To establish baseline safety and predict response, the following labs are recommended:
| Test | Purpose | Target Range |
|---|---|---|
| Complete Blood Count (CBC) | Detect anemia, leukopenia | Hb ≥ 12 g/dL (female), ≥ 13 g/dL (male); WBC ≥ 4,000/µL |
| Serum Creatinine & eGFR | Renal function assessment | Creatinine ≤ 1.2 mg/dL; eGFR ≥ 30 mL/min/1.73 m² |
| Liver Function Panel | Baseline hepatic status | ALT ≤ 40 U/L; AST ≤ 40 U/L; bilirubin ≤ 1.2 mg/dL |
| Glutathione Level (if available) | Identify deficiency | Whole blood: 0.8–2.5 µmol/g Hb |
| Coagulation Profile (PT/INR) | Assess synthetic function | PT ≤ 13 seconds; INR ≤ 1.2 |
Results outside target ranges should prompt specialist consultation before proceeding.
Dosage and Administration Protocols
GlutaOne 1200mg is supplied as a lyophilized powder for intravenous reconstitution. Standard regimen in clinical trials:
- Loading Dose: 1,200 mg (one vial) administered IV over 30 minutes, 3 times per week for 4 weeks.
- Maintenance Dose: 1,200 mg once weekly thereafter, based on response and tolerance.
- Adjunctive Infusions: Some clinicians add 500 mg of vitamin C to the infusion to enhance glutathione recycling, though evidence is limited.
“In my practice, I ensure that the infusion rate does not exceed 2 mL/min to minimize vasodilatory symptoms,” says Dr. Amelia Reyes, hepatologist at a tertiary care center.
Potential Adverse Reactions and Monitoring
Common side effects observed in the Phase III trial (n = 312) include:
| Adverse Event | Incidence | Management |
|---|---|---|
| Injection‑site irritation | 8.7 % | Apply cold compress; rotate sites. |
| Headache | 5.4 % | Analgesics (acetaminophen 500 mg PRN). |
| Transient nausea | 4.2 % | Administer anti‑emetic 30 min before infusion. |
| Flushing or mild hypotension | 2.9 % | Monitor vitals; slow infusion rate. |
Severe reactions (anaphylaxis, severe bronchospasm) occurred in <0.2 % of patients; emergency resuscitative equipment must be available.
Drug Interactions and Contraindications
Key interactions to evaluate:
- Acetaminophen